Boris Pasche: Karmanos Cancer Institute Leads Innovation in Cancer and Hematologic Disease Treatment
Boris Pasche, President and CEO at Karmanos Cancer Institute, shared a post on LinkedIn:
“Karmanos Cancer Institute continues to lead in medical science by providing patients with exceptional treatment opportunities for cancer and hematologic diseases.
As a pioneer in Theranostics, phase I trials, medical devices, and now gene therapy for hemophilia, Karmanos exemplifies its mission to transform care, research, and education in these fields through courage, commitment, and compassion.
With 17 locations throughout Michigan, Karmanos also offers second opinions, often introducing patients to novel therapies they may not have previously considered.
For more information on their groundbreaking work, check out this article: Karmanos is first independent cancer center to treat hemophilia B with new gene therapy.”
Stay updated with Hemostasis Today.
-
Jun 28, 2026, 10:34Heghine Khachatryan: Menarche as the First ‘Bleeding Challenge’
-
Jun 28, 2026, 10:13Mohammed Alharbi: Assessing Warfarin Management and Anticoagulation Quality in Older Populations
-
Jun 28, 2026, 10:03Rick Kapur: Current Understanding of FNAIT Regarding Diagnostics, Pathophysiology and Management
-
Jun 28, 2026, 09:55Utkarsh Pandey: Japan Approves Wayrilz for ITP Patients
-
Jun 28, 2026, 09:41Sung-mok Jung: How Environmental Drivers Influence SFTS Occurrence
-
Jun 28, 2026, 05:17Burcu Tunakan: Turning Collaboration into Better Outcomes for People with Hemophilia
-
Jun 28, 2026, 05:08Kathrine Kaspersen: The Power of Voluntary Plasma Donation
-
Jun 28, 2026, 04:55Sana Helani: Challenging Common Assumptions in Anemia Management
-
Jun 28, 2026, 04:55Samwel Mikaye: The Collapse of Coagulation Control in Disseminated Intravascular Coagulation